• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characterization of Spray-Dried Powders Using a Coated Alberta Idealized Nasal Inlet.使用带涂层的阿尔伯塔理想化鼻腔入口对喷雾干燥粉末进行表征。
J Aerosol Med Pulm Drug Deliv. 2025 Feb;38(1):1-12. doi: 10.1089/jamp.2024.0029. Epub 2025 Jan 13.
2
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
3
Storage and in-use stability of an excipient enhanced growth (EEG) synthetic lung surfactant powder formulation.一种辅料增强生长(EEG)型合成肺表面活性剂粉末制剂的储存稳定性及使用稳定性
Drug Dev Ind Pharm. 2025 Jul;51(7):747-757. doi: 10.1080/03639045.2025.2508845. Epub 2025 May 26.
4
Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease.用于非甾体抗炎药(NSAID)诱发的呼吸道疾病的口服和鼻内阿司匹林脱敏疗法。
Cochrane Database Syst Rev. 2025 Jan 7;1(1):CD013476. doi: 10.1002/14651858.CD013476.pub2.
5
Saline irrigation for allergic rhinitis.用于变应性鼻炎的盐水冲洗
Cochrane Database Syst Rev. 2018 Jun 22;6(6):CD012597. doi: 10.1002/14651858.CD012597.pub2.
6
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
7
Different types of intranasal steroids for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的不同类型鼻内类固醇
Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011993. doi: 10.1002/14651858.CD011993.pub2.
8
Physiologically Based Biopharmaceutic Lung Deposition Modeling to Guide Clinical Device Transition of Protein A from a Nebulizer to a Dry Powder Inhaler.基于生理学的生物药剂学肺部沉积建模,以指导蛋白A从雾化器向干粉吸入器的临床器械转换
Mol Pharm. 2025 Jul 7;22(7):3693-3701. doi: 10.1021/acs.molpharmaceut.4c01387. Epub 2025 Jun 25.
9
Nasal decongestants in monotherapy for the common cold.用于普通感冒单一疗法的鼻减充血剂。
Cochrane Database Syst Rev. 2016 Oct 17;10(10):CD009612. doi: 10.1002/14651858.CD009612.pub2.
10
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁及以上成人和儿童慢性哮喘比较效果的系统评价与经济学分析
Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190.

本文引用的文献

1
Characterizing regional drug delivery within the nasal airways.描述鼻腔气道内的区域性药物输送。
Expert Opin Drug Deliv. 2024 Apr;21(4):537-551. doi: 10.1080/17425247.2024.2336494. Epub 2024 Apr 3.
2
Visualization of nasal powder distribution using biomimetic human nasal cavity model.使用仿生人类鼻腔模型可视化鼻用粉剂分布情况。
Acta Pharm Sin B. 2024 Jan;14(1):392-404. doi: 10.1016/j.apsb.2023.06.007. Epub 2023 Jun 13.
3
What Are the Key Anatomical Features for the Success of Nose-to-Brain Delivery? A Study of Powder Deposition in 3D-Printed Nasal Casts.经鼻入脑给药成功的关键解剖学特征有哪些?3D打印鼻模中粉末沉积的研究。
Pharmaceutics. 2023 Nov 23;15(12):2661. doi: 10.3390/pharmaceutics15122661.
4
Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.通过双靶向粉末制剂中和 SARS-CoV-2 的单克隆抗体。
J Control Release. 2023 Jun;358:128-141. doi: 10.1016/j.jconrel.2023.04.029. Epub 2023 Apr 30.
5
In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery.棕榈酸帕利哌酮载入立方液晶纳米载体的体外评价-对鼻内递送到脑内有效。
Int J Nanomedicine. 2023 Mar 1;18:1085-1106. doi: 10.2147/IJN.S397650. eCollection 2023.
6
Optimising nasal powder drug delivery - Characterisation of the effect of excipients on drug absorption.优化鼻用粉末药物递送 - 辅料对药物吸收影响的表征。
Int J Pharm. 2023 Feb 25;633:122630. doi: 10.1016/j.ijpharm.2023.122630. Epub 2023 Jan 20.
7
In Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: Comparison with In Vivo Gamma Scintigraphy.鼻腔喷雾在理想化鼻腔入口处的体外局部沉积:与体内伽马闪烁成像的比较。
Pharm Res. 2022 Nov;39(11):3021-3028. doi: 10.1007/s11095-022-03388-7. Epub 2022 Sep 15.
8
Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterization.鼻腔内递呈含佐剂(LecA+GLA-3 M-052 脂质体)的合成溶组织内阿米巴疫苗:体外特性鉴定。
Int J Pharm. 2022 Oct 15;626:122141. doi: 10.1016/j.ijpharm.2022.122141. Epub 2022 Sep 2.
9
Inhalable microparticle platform based on a novel shell-forming lipid excipient and its feasibility for respirable delivery of biologics.基于新型成壳脂质赋形剂的吸入型微粒平台及其用于生物制剂可吸入递送的可行性。
Eur J Pharm Biopharm. 2022 Aug;177:308-322. doi: 10.1016/j.ejpb.2022.07.013. Epub 2022 Jul 26.
10
In Vitro Anatomical Models for Nasal Drug Delivery.用于鼻腔给药的体外解剖模型
Pharmaceutics. 2022 Jun 26;14(7):1353. doi: 10.3390/pharmaceutics14071353.

使用带涂层的阿尔伯塔理想化鼻腔入口对喷雾干燥粉末进行表征。

Characterization of Spray-Dried Powders Using a Coated Alberta Idealized Nasal Inlet.

作者信息

Duong Kelvin, Aisenstat Maximilian, Chen John Z, Murphy Brynn, Tavernini Scott, Wang Hui, Reiz Béla, Zheng Jing, Whittal Randy, McClary Wynton D, Gerhardt Alana, Fox Christopher B, Finlay Warren H, Vehring Reinhard, Martin Andrew R

机构信息

Department of Mechanical Engineering, University of Alberta, Edmonton, Canada.

Access to Advanced Health Institute (AAHI), Seattle, Washington, USA.

出版信息

J Aerosol Med Pulm Drug Deliv. 2025 Feb;38(1):1-12. doi: 10.1089/jamp.2024.0029. Epub 2025 Jan 13.

DOI:10.1089/jamp.2024.0029
PMID:39804033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11839532/
Abstract

Dry powders offer the potential to increase stability and reduce cold-chain requirements associated with the distribution of vaccines and other thermally sensitive products. The Alberta Idealized Nasal Inlet (AINI) is a representative geometry for characterization of nasal products that may prove useful in examining intranasal delivery of powders. Spray-dried trehalose powders were loaded at 10, 20, and 40 mg doses into active single-dose devices. Primary particle sizes (∼50 = 10 µm for powder A and 25 µm for powder B), and sizes dispersed by devices, were evaluated using laser diffraction. The interior of the AINI was coated with a glycerol-surfactant mixture to mitigate particle bounce, and flow rates of 7.5 or 15 L/min were drawn through the AINI. Deposition of trehalose powder was determined in the four regions of the AINI (vestibule, turbinates, olfactory, and nasopharynx), a downstream preseparator, and an absolute filter (representing lung deposition) using liquid chromatography coupled with mass spectrometry. Coating the AINI was effective in mitigating particle bounce for both trehalose powders. No difference in regional nasal deposition was observed when testing at a flow rate of 7.5 versus 15 L/min. A high fraction of both powders penetrated past the vestibule and deposited in the turbinates and nasopharynx for all loaded doses. For powder A, a non-negligible fraction of the recovered dose (up to 7%) is deposited on the filter, representing potential lung exposure. Conversely, a negligible fraction of the total recovered dose was deposited on the filter for powder B. Powders with a larger primary particle size showed reduced penetration through the nasal airways while maintaining high turbinate deposition. Optimized spray-dried powders offer the potential to target delivery to the peripheral nasal airways based on powder particle size while reducing lung exposure.

摘要

干粉剂有可能提高稳定性,并减少与疫苗及其他热敏产品分发相关的冷链需求。艾伯塔理想化鼻道入口(AINI)是用于表征鼻用产品的一种代表性几何结构,可能有助于研究粉末的鼻内给药情况。将喷雾干燥的海藻糖粉以10毫克、20毫克和40毫克的剂量装入单剂量活性装置中。使用激光衍射法评估了初级粒径(粉末A约为50±10微米,粉末B为25微米)以及装置分散后的粒径。AINI内部涂有甘油 - 表面活性剂混合物以减轻颗粒反弹,并以7.5或15升/分钟的流速通过AINI抽取气流。使用液相色谱 - 质谱联用技术,在AINI的四个区域(前庭、鼻甲、嗅觉区和鼻咽)、下游预分离器和绝对过滤器(代表肺部沉积)中测定海藻糖粉的沉积情况。对两种海藻糖粉而言,给AINI涂层都能有效减轻颗粒反弹。在7.5升/分钟与15升/分钟的流速下进行测试时,未观察到区域鼻腔沉积有差异。对于所有装载剂量,两种粉末中很大一部分都穿过前庭并沉积在鼻甲和鼻咽中。对于粉末A,回收剂量中不可忽略的一部分(高达7%)沉积在过滤器上,这代表有潜在的肺部暴露风险。相反,粉末B沉积在过滤器上的总回收剂量比例可忽略不计。初级粒径较大的粉末在保持高鼻甲沉积的同时,穿过鼻气道的渗透率降低。优化后的喷雾干燥粉末有可能根据粉末粒径将药物靶向递送至外周鼻气道,同时减少肺部暴露。